Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ Vaccine against Malaria in Healthy Adults
NCT05604521Phase 1Terminated
- Sponsor
- Sanaria Inc.
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sanaria PfSPZ Vaccine in malaria (4 arms), sponsored by Sanaria Inc. Primary endpoint: Adverse Events. Started Dec 2022; status: terminated.
02
Drugs
Sanaria PfSPZ Vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05604521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604521.